OncLive® Teams Up with Ohio State University Comprehensive Cancer Center – James in Strategic Alliance Partnership Program

Share Article

The Alliance Shares the Latest Advances in the Center’s Treatment, Research and Educational Programs.

News Image
"This alliance will help accomplish our common goal—the eradication of cancer,” said Mike J. Hennessy Jr., senior vice president of the Oncology Specialty Group, which includes OncLive, and Specialty Pharmacy at Michael J. Hennessy Associates, Inc.

OncLive® and the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard Solove Research Institute (OSUCCC – James) have entered into a partnership to raise awareness about cancer treatment, research and education through OncLive’s Strategic Alliance Partnership program.

In the new partnership, OncLive’s editorial and marketing teams will highlight the latest cancer-related news from OSUCCC – James, an innovative institution that strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. The OSUCCC – James is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. As the cancer program’s 306-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. At 21 floors with more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.

“We are excited about our new partnership with OSUCCC – James and the chance it will afford both organizations to share the latest advances in the center’s treatment, research and educational programs. This alliance will help accomplish our common goal—the eradication of cancer,” said Mike J. Hennessy Jr., senior vice president of the Oncology Specialty Group, which includes OncLive, and Specialty Pharmacy at Michael J. Hennessy Associates, Inc.

OSUCCC – James joins more than 40 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.

“The Strategic Alliance Partnership program serves everyone committed to fighting cancer. When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease,” Hennessy added.

About OncLive®
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. family of businesses, based in Plainsboro, N.J. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE™ magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit http://www.OncLive.com.

For more information on the OSUCCC – James, please visit http://cancer.osu.edu/.

###

Media Contacts:
For OncLive: Becky Taylor, 609.240.6886, becky(at)btaylorpa(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Becky Taylor
OncLive
+1 609-240-6886
Email >
@OncLive
since: 05/2009
Follow >
Visit website